*WENJUN ZHU¹, Rinako Tanaka¹, Tetsuo Matsuzaki¹, Hiroyuki Mizoguchi¹, Kaibuchi Kozo⁵, Ozaki Norio², Toshitaka Nabeshima⁴, Taku Nagai³, Kiyofumi Yamada¹ (1. Neuropsychopharmacology and Hospital Pharmacy, Graduate school of medicine, Nagoya University, Nagoya,Aichi, Japan, 2. Department of Psychiatry, Nagoya University Graduate School of Medicine, Nag oya, Aichi, Japan, 3. Division of Behavioral Neuropharmacology, International center for brain sci ence, Fujita Health University, Aichi, Japan, 4. Advanced Diagnostic System Research Laboratory Fujita Health University, Gra duate School of Health Sciences & Aino University, Toyoake, Aichi, Japan., 5. Division of Cell Biology, International Center for Brain Science(ICBS), Fuji ta Health University, Aichi, Japan)

*Shunta Okabe¹, Keishun Iwao², Emi Komai², Yuki Ozaki², Takashi Kitsukawa^3,4,5, Chieko Koike^2,4,5 (1. Grad Sch Pharm, Ritsumeikan Univ, Shiga, Japan , 2. Dept Pharm, Ritsumeikan Univ, Shiga, Japan , 3. Dept Lif Sci, Ritsumeikan Univ, Shiga, Japan , 4. Center for Systems Vision Sci, Research Org for Sci and Tech, Ritsumeikan Univ, Shiga, Japan, 5. Ritsumeikan Global Innovation Research Org (R-GIRO), Ritsumeikan Univ, Shiga, Japan)

*Masaki Maehara¹, Daisuke Kobayashi², Masayasu Sugiyama¹ (1. Sugiyama Pharmacy , 2. Department of Clinical Pharmacy and Pharmaceutical Care, Faculty of Pharmaceutical Sciences, Kyushu University)